Arafura Rare Earths (ASX:ARU) Locks 500tpa Traxys Deal Aimed Squarely At US Supply

The offtake book keeps growing, but the contract still hinges on a Final Investment Decision the market is still waiting for.

Arafura Rare Earths (ASX:ARU) has signed a binding term sheet with Traxys North America to supply 500 tonnes per annum of NdPr oxide and 7.5 tonnes per annum of dysprosium-terbium oxide from the Nolans Project. The deal runs five years with a two-year extension option, with pricing tied to global seaborne indices like Benchmark Minerals Intelligence or S&P Platts North America.

The strategic angle matters more than the volume. Traxys has flagged its intention to channel the product into the US supply chain, including potential supply into US EXIM’s Project Vault. That positions Arafura’s NdPr as a building block of America’s onshoring push across autos, defence, and advanced tech.

This sits on top of the existing Traxys Europe agreement for up to 300 tonnes per annum announced in March 2025. The offtake book continues to grow methodically, and management is leaning into the geopolitical narrative now driving sovereign capital into rare earths.

But there is a catch. The agreement is conditional on Arafura taking a Final Investment Decision on Nolans, which the market has been waiting on for several quarters.

Why Traxys keeps coming back to Nolans

Traxys is not a name retail investors always recognise, but it is a serious counterparty. The group trades over 65 commodities, runs 20 global offices, and turns over roughly US$10 billion a year. When a trader of that scale signs a second binding term sheet with a pre-production junior, it tells you something about how thin the non-Chinese NdPr pipeline really is.

The pricing structure also reads better than the historic norm. Linking the contract to independent seaborne indices rather than a fixed floor protects Arafura’s upside if NdPr re-rates, which several Western governments are arguably engineering through their procurement frameworks.

Our concern is that none of this is new in spirit. Hyundai, Kia, Siemens Gamesa, and Traxys Europe were all already on the dance card. This deepens the book but does not change the fundamental gating item.

The offtake book is now well past the 66% mark

Adding 500 tonnes per annum to the existing 300 tonnes from Traxys Europe, on top of binding agreements with Hyundai, Kia and Siemens Gamesa, pushes contracted volume meaningfully higher against Nolans’ nameplate of 4,440 tonnes per annum. That is exactly the kind of de-risked revenue profile project financiers want to see.

It also strengthens Arafura’s hand on the remaining offtake. With a growing portion of production already spoken for under index-linked pricing, the company can hold out for better terms on the uncontracted balance rather than discounting to fill the book.

The DyTb component is also worth flagging. Dysprosium and terbium are the heavy rare earths Western magnet makers cannot easily source outside China, and even 7.5 tonnes per annum carries strategic weight well beyond the headline tonnage.

FID is still the only variable that matters

The conditions precedent are explicit. Long form documentation is targeted within six months, but the whole agreement hinges on Arafura taking FID on Nolans. Without that, this term sheet, and arguably the broader funding stack, remains optionality rather than committed capital.

We have written previously about the puzzling gap between Arafura’s funding position, with more than A$1.35 billion in sovereign-backed commitments lined up, and a share price that has spent most of the past year well below the October 2025 placement level. The Traxys North America deal does not close that gap on its own.

The Investors Takeaway for Arafura Rare Earths

The Traxys North America deal is a quality data point. It adds index-linked revenue, embeds Arafura further into the US critical minerals architecture, and puts heavy rare earths into the contracted mix at meaningful scale for the first time.

What it does not do is change the shape of the investment question. Patient holders are still waiting for FID, and every offtake signed before that decision arguably makes the eventual approval easier to justify. Investors can read our previous coverage of where Arafura sits on the path to FID at stocksdownunder.